HMGA2 Regulates Transcription of the Imp2 Gene via an Intronic Regulatory Element in Cooperation with Nuclear Factor-κB
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
IMP2 (insulin-like growth factor-II mRNA binding protein 2) is an oncofetal protein that is aberrantly expressed in several types of cancer. We recently identified the Imp2 gene as a target gene of the architectural transcription factor HMGA2 (high mobility group A2) and its tumor-specific truncated form HMGA2Tr. In this study, we investigated the mechanism via which HMGA2 regulates Imp2 gene expression. We show that HMGA2 and HMGA2Tr directly regulate transcription of the Imp2 gene by binding to an AT-rich regulatory region located in the first intron. In reporter experiments, we show that this AT-rich regulatory region mimics the response of the endogenous Imp2 gene to HMGA2 and HMGA2Tr. Furthermore, we show that a consensus nuclear factor-κB (NF-κB) binding site located immediately adjacent to the AT-rich regulatory region binds NF-κB and that NF-κB and HMGA2 cooperate to regulate Imp2 gene expression. Finally, we provide evidence that there is a strong and statistically significant correlation between HMGA2 and IMP2 gene expression in human liposarcomas. (Mol Cancer Res 2007;5(4):363–72)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Nielsen, J., Christiansen, J., Lykke-Andersen, J., Johnsen, A. H., Wewer, U. M., & Nielsen, F. C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1262 · Cited by 721
Thanos, D., & Maniatis, T. (1992) · Cell · doi:10.1016/0092-8674(92)90554-p · Cited by 617
Research works printed but not linked: 42
- Leeds P, Kren BT, Boylan JM, et al. Developmental regulation of CRD-BP, an RNA-binding protein that stabilizes c-myc mRNA in vitro. Oncogene 1997;14:1279–86. · DOI
- Mori H, Sakakibara S, Imai T, et al. Expression of mouse igf2 mRNA-binding protein 3 and its implications for the developing central nervous system. J Neurosci Res 2001;64:132–43. · DOI · Paper page
- Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997;14:2729–33. · DOI · Paper page
- Yaniv K, Yisraeli JK. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene 2002;287:49–54. · DOI · Paper page
- Yisraeli JK. VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins. Biol Cell 2005;97:87–96. · DOI · Paper page
- Lu M, Nakamura RM, Dent ED, et al. Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. Am J Pathol 2001;159:945–53. · DOI
- Zhang JY, Chan EK, Peng XX, et al. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol 2001;100:149–56. · DOI
- Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003;9:5120–6.
- Brants JR, Ayoubi TA, Chada K, Marchal K, Van de Ven WJ, Petit MM. Differential regulation of the insulin-like growth factor II mRNA-binding protein genes by architectural transcription factor HMGA2. FEBS Lett 2004;569:277–83. · DOI · Paper page
- Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J, Hameister H. The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 1998;23:350–7. · doi:10.1002/(sici)1098-2264(199812)23:4<350::aid-gcc10>3.0.co;2-e
- Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996;13:2439–46.
- Zhou X, Benson KF, Przybysz K, et al. Genomic structure and expression of the murine Hmgi-c gene. Nucleic Acids Res 1996;24:4071–7. · DOI
- Hess JL. Chromosomal translocations in benign tumors: the HMGI proteins. Am J Clin Pathol 1998;109:251–61. · doi:10.1093/ajcp/109.3.251
- Tallini G, Dal Cin P. HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors. Adv Anat Pathol 1999;6:237–46. · DOI · Paper page
- Bustin M, Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 1996;54:35–100. · DOI · Paper page
- Ashar HR, Fejzo MS, Tkachenko A, et al. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 1995;82:57–65. · DOI · Paper page
- Kools PF, Wanschura S, Schoenmakers EF, et al. Identification of the chromosome 12 translocation breakpoint region of a pleomorphic salivary gland adenoma with t(1;12)(p22;q15) as the sole cytogenetic abnormality. Cancer Genet Cytogenet 1995;79:1–7. · doi:10.1016/0165-4608(94)00137-z
- Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Res 2002;12:996–1006. · DOI · Paper page
- Noro B, Licheri B, Sgarra R, et al. Molecular dissection of the architectural transcription factor HMGA2. Biochemistry 2003;42:4569–77. · DOI
- Borrmann L, Schwanbeck R, Heyduk T, et al. High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity. Nucleic Acids Res 2003;31:6841–51. · DOI
- Arrigoni G, Doglioni C. Atypical lipomatous tumor: molecular characterization. Curr Opin Oncol 2004;16:355–8. · doi:10.1097/01.cco.0000127878.85125.53
- Dei Tos AP, Doglioni C, Piccinin S, et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 2000;190:531–6. · DOI · Paper page
- Forus A, Larramendy ML, Meza-Zepeda LA, et al. Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases. Cancer Genet Cytogenet 2001;125:100–11. · DOI
- Tallini G, Dal Cin P, Rhoden KJ, et al. Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: immunohistochemical reactivity correlates with karyotypic alterations. Am J Pathol 1997;151:37–43.
- Trahan S, Erickson-Johnson MR, Rodriguez F, et al. Formation of the 12q14-q15 amplicon precedes the development of a well-differentiated liposarcoma arising from a nonchondroid pulmonary hamartoma. Am J Surg Pathol 2006;30:1326–9. · doi:10.1097/01.pas.0000213257.69478.2f
- Pentimalli F, Dentice M, Fedele M, et al. Suppression of HMGA2 protein synthesis could be a tool for the therapy of well differentiated liposarcomas overexpressing HMGA2. Cancer Res 2003;63:7423–7.
- Aman P, Ron D, Mandahl N, et al. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 1992;5:278–85. · DOI · Paper page
- Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993;363:640–4. · DOI · Paper page
- Rabbitts TH, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993;4:175–80. · DOI · Paper page
- Turc-Carel C, Limon J, Dal Cin P, Rao U, Karakousis C, Sandberg AA. Cytogenetic studies of adipose tissue tumors. II. Recurrent reciprocal translocation t(12;16)(q13;p11) in myxoid liposarcomas. Cancer Genet Cytogenet 1986;23:291–9. · DOI · Paper page
- Reeves R, Beckerbauer L. HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 2001;1519:13–29. · DOI · Paper page
- Yie J, Merika M, Munshi N, Chen G, Thanos D. The role of HMG I(Y) in the assembly and function of the IFN-beta enhanceosome. EMBO J 1999;18:3074–89. · DOI · Paper page
- Fedele M, Visone R, De Martino I, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006;9:459–71. · DOI · Paper page
- Tessari MA, Gostissa M, Altamura S, et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol 2003;23:9104–16. · DOI · Paper page
- Bagga R, Michalowski S, Sabnis R, Griffith JD, Emerson BM. HMG I/Y regulates long-range enhancer-dependent transcription on DNA and chromatin by changes in DNA topology. Nucleic Acids Res 2000;28:2541–50. · DOI
- Reeves R. HMGA proteins: flexibility finds a nuclear niche? Biochem Cell Biol 2003;81:185–95. · DOI
- Mantovani F, Covaceuszach S, Rustighi A, et al. NF-κB mediated transcriptional activation is enhanced by the architectural factor HMGI-C. Nucleic Acids Res 1998;26:1433–9. · DOI
- Moynagh PN. The NF-κB pathway. J Cell Sci 2005;118:4589–92. · DOI · Paper page
- Crombez KR, Vanoirbeek EM, Van de Ven WJ, Petit MM. Transactivation functions of the tumor-specific HMGA2/LPP fusion protein are augmented by wild-type HMGA2. Mol Cancer Res 2005;3:63–70. · DOI
- Sambrook J, Russell DW. Molecular Cloning: a Laboratory Manual. 3rd. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2001.
- Wadman IA, Osada H, Grutz GG, et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J 1997;16:3145–57. · DOI · Paper page
- Polito P, Dal Cin P, Debiec-Rychter M, Hagemeijer A. Human solid tumors: cytogenetic techniques. Methods Mol Biol 2003;220:135–50. · doi:10.1385/1-59259-363-1:135
Cited by
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis
The MAGIC investigators, Voight, B. F., The GIANT Consortium, Scott, L. J., Steinthorsdottir, V., Morris, A. P., Dina, C., Welch, R. P., Zeggini, E., Huth, C., et al. (2010) · Nature Genetics · doi:10.1038/ng.609 · Cited by 1,761
Bell, J. L., Wächter, K., Mühleck, B., Pazaitis, N., Köhn, M., Lederer, M., & Hüttelmaier, S. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1186-z · Cited by 783
Barrett, L. W., Fletcher, S., & Wilton, S. D. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0990-9 · Cited by 605
Cabezas-Wallscheid, N., Klimmeck, D., Hansson, J., Lipka, D. B., Reyes, A., Wang, Q., Weichenhan, D., Lier, A., von Paleske, L., Renders, S., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.07.005 · Cited by 589
Copley, M. R., Babovic, S., Benz, C., Knapp, D. J. H. F., Beer, P. A., Kent, D. G., Wohrer, S., Treloar, D. Q., Day, C., Rowe, K., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2783 · Cited by 342
Metadata
- Authors
- Cleynen, I., Brants, J. R., Peeters, K., Deckers, R., Debiec-Rychter, M., Sciot, R., Van de Ven, W. J. M., & Petit, M. M. R.
- Venue
- Molecular Cancer Research
- Published
- 2007-04-01
- Volume
- 5
- Issue
- 4
- Pages
- 363-372
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2162324253
- Cited by
- 92
- References
- 3
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HMGA2 Regulates Transcription of the Imp2 Gene via an Intronic Regulatory Element in Cooperation with Nuclear Factor-κB. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-06-0331
- The paper
- Cleynen, I., Brants, J. R., Peeters, K., Deckers, R., Debiec-Rychter, M., Sciot, R., Van de Ven, W. J. M., & Petit, M. M. R. (2007). HMGA2 Regulates Transcription of the Imp2 Gene via an Intronic Regulatory Element in Cooperation with Nuclear Factor-κB. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-06-0331
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.